Mass Dynamics

Mass Dynamics operates within the biotechnology and HealthTech sectors, providing a specialized software-as-a-service (SaaS) platform for life scientists. Founded in Melbourne, Australia, the company has conflicting founding dates reported as 2015, 2018, and 2019. The founding team combines deep scientific expertise with extensive software development experience. Co-founders Professor Andrew Webb and Dr. Giuseppe Infusini are career proteomics scientists who faced the challenges the platform now solves. Co-founders Paula Burton (CEO) and Aaron Triantafyllidis come from enterprise, startup, and government sectors, building software products and multidisciplinary teams. Burton, who studied Computer Science, previously spent a decade at a technology consultancy before establishing Mass Dynamics.

The company's primary offering is a cloud-based, integrated environment designed to analyze mass spectrometry (MS) data, a technique used to measure the mass-to-charge ratio of ions. This platform targets the proteomics market, enabling researchers, biologists, clinicians, and omics experts to process, analyze, visualize, and securely share large, complex datasets without needing to manage underlying hardware infrastructure. The service aims to accelerate scientific discovery, aid in the development of new drugs, and help identify disease mechanisms by transforming raw data into actionable knowledge. The platform is designed for accessibility via a web browser and supports high-throughput studies by streamlining analysis and improving collaboration. Key clients include academic institutions and corporations like Monash University, the Hudson Institute, and CSL.

The Mass Dynamics platform features modules for automated quality control, interactive data visualization (such as volcano plots, heatmaps, and violin plots), and collaborative tools. Version 2.0 of the software introduced a modular, drag-and-drop framework that allows users to customize analyses and create templates, expediting insight generation. Users can upload data from pre-processing tools like MaxQuant and share findings securely with collaborators or make them public. Revenue is generated through this SaaS model, with the company reporting a sevenfold revenue growth as of December 2023. The company has secured funding through several rounds, including an accelerator/incubator round in October 2020 and a Series 1 venture round in December 2023, with total funding reported between $1.2M and $4M. Investors include Rampersand, Possible Ventures, Startmate, and Blackbird Ventures.

Keywords: proteomics software, mass spectrometry data analysis, bioinformatics, life sciences, drug discovery, SaaS, computational biology, data visualization, clinical research, HealthTech, biotech software, omics data, scientific collaboration, research tools, biomarker discovery, quantitative proteomics, data processing, proteome research, lab software, scientific analysis